Skip to content

CTNM

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ · Healthcare · Biotechnology · US

$16.70
−4.95%
Ask drillr
0
Insider buys (3m)
8
Insider sells (3m)
-$1.0M
Net value (3m)
+48.2%
Price return (3m)
Form 4 filings
DateInsiderActivitySharesPrice
Aug 3, 2026Stengone Carmine N. · director, officer: CEO and PresidentM-Exempt2,500$1.01
Aug 3, 2026Stengone Carmine N. · director, officer: CEO and PresidentSale2,500$16
Jul 10, 2026Lorrain Daniel S. · officer: Chief Scientific OfficerM-Exempt25$1.01
Jul 10, 2026Lorrain Daniel S. · officer: Chief Scientific OfficerSale25$16
Jul 10, 2026Lorrain Daniel S. · officer: Chief Scientific OfficerM-Exempt1,015$1.01
Jul 8, 2026Stengone Carmine N. · director, officer: CEO and PresidentM-Exempt2,500$1.01
Jul 8, 2026Stengone Carmine N. · director, officer: CEO and PresidentSale2,500$16
Jul 2, 2026Lorrain Daniel S. · officer: Chief Scientific OfficerM-Exempt28,826$1.01
Jul 2, 2026Lorrain Daniel S. · officer: Chief Scientific OfficerSale2,501$16
Jul 2, 2026Lorrain Daniel S. · officer: Chief Scientific OfficerSale5,852$16
Jul 2, 2026Lorrain Daniel S. · officer: Chief Scientific OfficerM-Exempt4,183$1.01
Jul 2, 2026Lorrain Daniel S. · officer: Chief Scientific OfficerSale28,826$16
Jul 1, 2026Watkins Tim · officer: CMO & Head of DevelopmentM-Exempt10,833$4.50
Jul 1, 2026Stengone Carmine N. · director, officer: CEO and PresidentSale10,000$16
Jul 1, 2026Stengone Carmine N. · director, officer: CEO and PresidentM-Exempt2,500$1.26
Jul 1, 2026Stengone Carmine N. · director, officer: CEO and PresidentM-Exempt7,500$1.01
Jul 1, 2026Watkins Tim · officer: CMO & Head of DevelopmentSale10,833$16
Jun 26, 2026Brady Todd R. · directorA-Award19,000$14
Jun 26, 2026Boyce Sarah · directorA-Award19,000$14
Jun 26, 2026Ignelzi Troy A. · directorA-Award19,000$14
Jun 26, 2026Schimmelpennink Evert B. · directorA-Award19,000$14
Jun 26, 2026Ware Olivia C · directorA-Award19,000$14
Jun 26, 2026Lyons-Williams Lori · directorA-Award19,000$14
Jun 26, 2026Miralles Gines Diego · directorA-Award19,000$14
Jun 1, 2026Lorrain Daniel S. · officer: Chief Scientific OfficerSale4,170$13
May 1, 2026Lorrain Daniel S. · officer: Chief Scientific OfficerSale300$14
May 1, 2026Lorrain Daniel S. · officer: Chief Scientific OfficerSale3,870$13
Apr 6, 2026Lorrain Daniel S. · officer: Chief Scientific OfficerSale4,170$13
Mar 2, 2026Watkins Tim · officer: CMO & Head of DevelopmentSale3,611$15
Mar 2, 2026Watkins Tim · officer: CMO & Head of DevelopmentM-Exempt3,611$4.50
Institutional positioning

13F filings over the trailing two quarters

New 22Increased 31Reduced 23Sold out 87
FilerActionSharesFiled
SUVRETTA CAPITAL MANAGEMENT, LLCUnchanged2,841,334May 15, 2026
JANUS HENDERSON GROUP PLCIncreased2,734,836May 18, 2026
JOHNSON & JOHNSONUnchanged1,979,173Mar 18, 2026
JOHNSON & JOHNSONReduced1,979,173May 13, 2026
FRANKLIN RESOURCES INCReduced1,839,227May 13, 2026
BALYASNY ASSET MANAGEMENT L.P.Reduced1,685,635May 15, 2026
MILLENNIUM MANAGEMENT LLCIncreased1,535,449May 15, 2026
BAKER BROS. ADVISORS LPUnchanged1,420,838May 15, 2026
RA CAPITAL MANAGEMENT, L.P.Reduced1,296,012May 15, 2026
PERCEPTIVE ADVISORS LLCReduced1,255,592May 29, 2026
VANGUARD CAPITAL MANAGEMENT LLCNew Position1,214,173May 15, 2026
FMR LLCUnchanged814,871May 15, 2026
IKARIAN CAPITAL, LLCIncreased807,874May 15, 2026
GREAT POINT PARTNERS LLCIncreased800,198May 15, 2026
LONGAEVA PARTNERS L.P.Increased732,088May 15, 2026

Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 3, 2026